Equities

Amphastar Pharmaceuticals Inc

Amphastar Pharmaceuticals Inc

Actions
  • Price (EUR)45.06
  • Today's Change0.49 / 1.10%
  • Shares traded200.00
  • 1 Year change-8.04%
  • Beta--
Data delayed at least 15 minutes, as of Nov 12 2024 07:13 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and injectable, inhalation, and intranasal products. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. Its segments include finished pharmaceutical products and API products. The finished pharmaceutical products segment manufactures, markets and distributes Primatene MIST, epinephrine, glucagon, phytonadione, lidocaine, enoxaparin, naloxone, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes RHI API and porcine insulin API for external customers and internal product development. Its pipeline has over 20 product candidates, including generic ANDAs, biosimilar, and others.

  • Revenue in USD (TTM)723.55m
  • Net income in USD157.72m
  • Incorporated2004
  • Employees1.76k
  • Location
    Amphastar Pharmaceuticals Inc11570 6th StRANCHO CUCAMONGA 91730United StatesUSA
  • Phone+1 (909) 980-9484
  • Fax+1 (302) 655-5049
  • Websitehttps://amphastar.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.